Korsana Emerges with $175M, Targeting a 'Best-in-Class' Alzheimer's Therapy

WALTHAM, Mass. – February 18, 2026 – A new, heavily funded contender has entered the high-stakes arena of Alzheimer’s disease treatment. Korsana Biosciences announced its emergence from stealth operations today, armed with $175 million in financing and a mission to develop what it calls potential “best-in-class” therapeutics for neurodegenerative diseases. The company’s initial focus is squarely on Alzheimer’s, with a lead candidate designed to overcome the significant safety and efficacy hurdles that have challenged currently approved therapies.

Korsana, founded in 2024, has attracted a formidable syndicate of healthcare investors. The funding includes a $25 million seed round from Fairmount and Venrock Healthcare Capital Partners, followed by a substantial $150 million Series A financing closed in September 2025. The Series A was co-led by Wellington Management and TCGX, with major participation from J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, and Foresite Capital. This financial backing is intended to propel Korsana’s lead program, KRSA-028, through crucial clinical milestones into 2028.

At the helm is President and CEO Jonathan Violin, Ph.D., a veteran biotech entrepreneur with a history of building successful companies like Viridian Therapeutics and Dianthus Therapeutics. “We are thrilled to announce the launch of Korsana with a mission to elevate expectations for patients suffering from devastating neurodegenerative diseases,” Dr. Violin stated. His leadership, combined with the significant capital injection, signals a serious effort to disrupt the current treatment paradigm.

A Crowded Field with Unmet Needs

Korsana is stepping into a landscape recently transformed by the arrival of the first disease-modifying therapies for Alzheimer's, such as Eisai and Biogen's Leqembi (lecanemab) and Eli Lilly's Donanemab. These antibody drugs, which target and clear amyloid-beta plaques from the brain, represent a major scientific achievement. However, their real-world impact has been tempered by modest efficacy, a high burden of care, and significant safety concerns.

Patients receiving these treatments, which are administered via regular intravenous infusions, must undergo frequent monitoring for a side effect known as Amyloid-Related Imaging Abnormalities (ARIA). ARIA can manifest as potentially dangerous brain swelling or microhemorrhages, creating a substantial risk that limits their use and adds to patient anxiety. This reality underscores a critical unmet need for safer, more effective, and more convenient options.

“Only two disease-modifying therapies have been approved to treat Alzheimer’s, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care,” Dr. Violin noted in his announcement. “Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s.”

The 'THETA' Advantage: A Smarter Delivery System

The cornerstone of Korsana’s strategy is its proprietary Therapeutic Targeting (THETA™) platform, a novel technology designed to solve one of the most persistent challenges in neurology: getting drugs across the protective blood-brain barrier (BBB). This highly selective membrane prevents nearly all large-molecule drugs, including antibodies, from reaching their targets in the brain in sufficient concentrations.

Korsana’s THETA™ platform utilizes a “shuttle” approach by engineering its antibodies to bind to the transferrin receptor (TfR1), a natural transport protein on the BBB. This essentially provides the drug with a VIP pass into the brain. While other companies have explored TfR1-based shuttles, Korsana claims its platform overcomes the limitations of earlier approaches.

KRSA-028, the company’s lead shuttled antibody, leverages this technology to achieve what is expected to be dramatically higher drug concentration inside the brain. The antibody itself targets amyloid-beta, the same plaque-forming protein addressed by current therapies, but the enhanced delivery could lead to more efficient and complete plaque clearance. Furthermore, the antibody has undergone sophisticated Fc engineering—modifications to its “tail” region—designed to preserve its plaque-clearing function while minimizing the immune-mediated toxicity that is believed to contribute to ARIA. This dual innovation in brain delivery and safety engineering is central to the company’s “best-in-class” claim.

“We believe Korsana is well positioned to overcome the limitations of not just first-generation Alzheimer’s therapies, but also of earlier shuttle technologies,” said Andrew Gottesdiener, M.D., a partner at Venrock and co-founder of Korsana.

A Foundation of Capital and Proven Expertise

Beyond the science, Korsana's emergence is a powerful story of strategic company building. The company is the latest spinout from Paragon Therapeutics, a discovery engine founded by Fairmount that specializes in designing complex biologics and launching new companies to advance them. Paragon, which also spawned successful biotechs like Apogee Therapeutics and Spyre Therapeutics, developed the THETA™ platform and discovered KRSA-028 in partnership with Korsana.

This pedigree, combined with the leadership of Dr. Violin, has clearly resonated with investors. The syndicate backing Korsana includes a mix of top-tier venture capital, public market investors, and the corporate venture arm of a major pharmaceutical company, Sanofi. This broad support not only provides financial runway but also validates the company's approach and potential market impact.

“We are excited to come together with the rest of this investor syndicate to support Korsana’s launch,” said Nilesh Kumar, Head of Biotech Private Investments at Wellington Management. “We look forward to seeing KRSA-028 and Korsana’s pipeline of innovative therapies advance through key clinical milestones in the coming years.”

The Road Ahead: Clinical Milestones and Patient Hopes

With its substantial funding, Korsana has a clear path toward proving its technology in the clinic. The company anticipates its financing will fund operations into 2028, allowing it to pursue critical clinical data that will either validate or challenge its ambitious claims.

Korsana has outlined a timeline for two pivotal data readouts. By mid-2027, the company expects to have initial data from healthy volunteers that will provide the first human look at KRSA-028’s safety, pharmacokinetics, and, most importantly, its ability to penetrate the central nervous system. This will be followed by a crucial proof-of-concept readout expected by the end of 2027, which aims to demonstrate amyloid plaque clearance in Alzheimer’s patients.

Success in these trials could pave the way for a therapy that not only works better but is also far more patient-friendly. KRSA-028 is designed for a low-volume subcutaneous route of administration, potentially replacing hours-long IV infusions with a simple injection. This convenience, paired with a potentially superior safety profile, represents the future of care that patients and their families have been waiting for. The coming years will reveal whether Korsana’s ambitious approach can truly redefine the standard of care for one of the world's most challenging diseases.